Drug Profile
Research programme: topical skin and hair disorder therapies - CervoMed
Alternative Names: HYG 102440; HYG 104; HYG 112; HYG 113; HYG 201; HYG 202; HYG 302; HYG 401; HYG 420; HYG 430; HYG-102440 (combination of HYG-102 and HYG-440); HYG-114; HYG-301; HYG-410; HYG-440; RES 102440; RES 440Latest Information Update: 17 Aug 2023
Price :
$50
*
At a glance
- Originator Hygeia Therapeutics
- Class Estradiol congeners; Hormones
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne; Alopecia; Hirsutism; Skin disorders
Most Recent Events
- 16 Aug 2023 EIP Pharma has merged with Diffusion Pharmaceuticals to form CervoMed
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acne in USA (Topical)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alopecia in USA (Topical)